Releases
Investors Face August Deadline in Erasca Securities Fraud Case
Investors who purchased Erasca, Inc. common stock between January 14, 2025, and April 26, 2026, have until August 10, 2026, to file as lead plaintiffs in a pending class action lawsuit. The litigation targets alleged misrepresentations regarding the company’s oncology drug candidate, ERAS-0015.























